High Tech Pharm Co

High Tech Pharm Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of High Tech Pharm Co (106190.KQ) as of Nov 2, 2026 is 9.74 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 12.75 % — a change of -23.63% (lower).

EBIT/Assets

9.74 %

YoY

-23.63%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of High Tech Pharm Co is 2025 9.74 % . Operating Income to Assets Ratio (EBIT/Assets) of High Tech Pharm Co was 2024 12.75 % . It decreases by -23.63% lower compared to the previous year.

The High Tech Pharm Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2017
2.75 KRW
Jan 1, 2018
1.57 KRW
Jan 1, 2019
-3.44 KRW
Jan 1, 2020
-2.59 KRW
Jan 1, 2021
-0.57 KRW
Jan 1, 2022
3.73 KRW
Jan 1, 2024
12.75 KRW
Jan 1, 2025
9.74 KRW
The High Tech Pharm Co EBIT/Assets history
YEAREBIT/AssetsYoY
9.74 %-23.63%
12.75 %+242.17%
3.73 %-754.02%
-0.57 %-77.98%
-2.59 %-24.67%
-3.44 %-319.34%
1.57 %-42.98%
2.75 %-37.22%
4.38 %-9.68%
4.84 %-34.53%
7.40 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

High Tech Pharm Co Stock analysis

What does High Tech Pharm Co do? High Tech Pharm Co., Ltd. generates revenue by manufacturing and selling raw materials specifically for injectable antibiotic products. The company's product portfolio consists of sterile imipenem, sterile cilastatin sodium, sterile blended imipenem and cilastatin sodium, injectable sterile meropenem, injectable sterile panipenem, faropenem, and other related pharmaceutical ingredients. These items are produced for use in the medical sector as active pharmaceutical components. The firm sells these antibiotic pharmaceutical ingredients to both domestic and overseas markets. As a Korea-based entity, it distributes its sterile products to buyers who require raw materials for injectable formulations. The company operates from its headquarters in Chungju, Chungcheongbuk-Do, where it utilizes its workforce to support this manufacturing and distribution model. High Tech Pharm Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about High Tech Pharm Co stock

Operating Income to Assets Ratio (EBIT/Assets) of High Tech Pharm Co is 9.74 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of High Tech Pharm Co changed from 12.75 % to 9.74 %, representing a -23.63% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) High Tech Pharm Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s High Tech Pharm Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — High Tech Pharm Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — High Tech Pharm Co